Asked by: Damien Egan (Labour - Bristol North East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of Yellow Card reporting for capturing cases of Topical Steroid Withdrawal.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department, with responsibility for ensuring medicines meet appropriate standards of safety, quality, and efficacy.
In 2021, the MHRA published a Public Assessment Report (PAR), reviewing the available evidence for topical steroid withdrawal (TSW) reactions, which can be found at the following link:
To inform this report, a comprehensive review of the available evidence was undertaken. This included an assessment of data from Yellow Card reports to identify suspected spontaneous cases of TSW reactions associated with topical corticosteroids on the Yellow Card database, as well as information from the published literature and other medicines regulators. The review considered whether regulatory action was required to minimise the risk of these events.
The PAR resulted in two Drug Safety Updates in 2021 and 2024 which aimed to raise awareness on the risk of TSW reactions and introduce new labelling. Both updates are available, respectively, at the following two links:
The MHRA uses the Medical Dictionary for Regulatory Activities (MedDRA) to code suspected adverse drug reactions reported by patients and healthcare professionals via the Yellow Card scheme. MedDRA is an international, clinically validated medical terminology used by regulatory authorities and the biopharmaceutical industry throughout the entire regulatory process, from pre-marketing to post-marketing safety monitoring. MedDRA is updated twice annually, and new terms can be proposed by any MedDRA users. Following the publication of the PAR, the term “Topical steroid withdrawal reaction” was added to MedDRA as a lower level term in version 24.1 and made available to users of the Yellow Card website in February 2022 as part of routine updates. This helps to ensure that more reports pertaining to TSW reactions are appropriately captured. The MHRA continues to closely monitor Yellow Card reports submitted for suspected TSW reactions.
The MHRA continues to engage with the British Association of Dermatologist who have also released a statement, which is available at the following link:
https://cdn.bad.org.uk/uploads/2024/02/22095550/Topical-Steroid-Withdrawal-Joint-Statement.pdf
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of removing the exceptionality requirement for Individual Funding Requires for Chemosaturation therapy and comparable intervention for people whose lives are at risk.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department and the National Health Service in England are committed to ensuring that cancer patients have timely access to treatment and tailored medical support. In 2016, NHS England concluded that there was insufficient evidence to make chemosaturation treatment available to patients on the NHS. NHS England is currently in the early stages of policy development for chemosaturation to treat metastatic uveal melanoma where surgery to remove or destroy affected cells and tissue in the liver is not feasible.
National Institute for Health and Care Excellence (NICE) guidance recommends that chemosaturation can be used for patients with secondary liver metastases resulting from a primary ocular melanoma, provided special arrangements are in place. A special arrangements recommendation states that clinicians using the procedure should inform the clinical governance lead in their trust, tell the patient about the uncertainties regarding the safety and efficacy of the procedure, and collect further data by means of audit or research. NICE is in the process of updating its guidance, with final guidance expected on 15 October 2026. The first committee meeting, to discuss the evidence, is expected to take place on 16 April 2026. Further information is available at the following link:
https://www.nice.org.uk/guidance/indevelopment/gid-ipg10448
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS England on the publication date for the draft commissioning policy for Chemosaturation therapy.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department and the National Health Service in England are committed to ensuring that cancer patients have timely access to treatment and tailored medical support. In 2016, NHS England concluded that there was insufficient evidence to make chemosaturation treatment available to patients on the NHS. NHS England is currently in the early stages of policy development for chemosaturation to treat metastatic uveal melanoma where surgery to remove or destroy affected cells and tissue in the liver is not feasible.
National Institute for Health and Care Excellence (NICE) guidance recommends that chemosaturation can be used for patients with secondary liver metastases resulting from a primary ocular melanoma, provided special arrangements are in place. A special arrangements recommendation states that clinicians using the procedure should inform the clinical governance lead in their trust, tell the patient about the uncertainties regarding the safety and efficacy of the procedure, and collect further data by means of audit or research. NICE is in the process of updating its guidance, with final guidance expected on 15 October 2026. The first committee meeting, to discuss the evidence, is expected to take place on 16 April 2026. Further information is available at the following link:
https://www.nice.org.uk/guidance/indevelopment/gid-ipg10448
Asked by: Callum Anderson (Labour - Buckingham and Bletchley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve diagnostic services for cancer in Buckingham and Bletchley constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving cancer services, including diagnostic capacity and treatment infrastructure, is a priority for the Government.
The Government is committed to meeting all three National Health Service cancer waiting time standards across England. We are committed to transforming diagnostic services and will support the NHS to meet demand through investment in new capacity, including magnetic resonance imaging and computed tomography scanners. As of December 2025, community diagnostic centres are now delivering additional tests and checks on 170 sites across the country.
The forthcoming National Cancer Plan will set out further details as to how patients across England, including in Buckingham and Bletchley, will benefit from improved diagnostic services and cancer care infrastructure.
Funding for cancer pathways is multi-layered. The integrated care board uses the core Government allocation to commission services from providers, including cancer-related activity. Specialised commissioning directs funding towards specialist areas of healthcare, such as paediatric oncology and chemotherapy.
The East of England Cancer Alliance has been allocated approximately £16 million of revenue funds for 2026/27 which will support targeted programmes of work. The process to allocate these funds is currently live. System priorities have been identified and funding requests have been submitted for consideration.
Asked by: Callum Anderson (Labour - Buckingham and Bletchley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of staffing levels for oncology services in Buckingham and Bletchley constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Residents of Bletchley who access oncology care would most likely attend Milton Keynes University Hospital which offers on-site chemotherapy and radiotherapy, the latter led by the Oxford University Hospitals NHS Foundation Trust. Workforce reviews are currently under way to ensure that this trust can accommodate increasing demand for services and to ensure that residents can access new treatments when they become available.
The National Cancer Plan, which will be published shortly, will highlight how we will reform our workforce to improve cancer patient outcomes, including for those patients in the Buckingham and Bletchley constituency. We will ensure that we have the right staff, in the right places, with the right skills, so patients can access quality care when and where they need it.
Asked by: Baroness Pidgeon (Liberal Democrat - Life peer)
Question to the Department for Transport:
To ask His Majesty's Government, with regard to the Road Safety Strategy, published on 7 January, what steps they will take to secure the linkage of police-recorded collision data and healthcare data between the Department for Transport, NHS England and the Department of Health and Social Care; and what the timescale is for that work.
Answered by Lord Hendy of Richmond Hill - Minister of State (Department for Transport)
The DfT, together with NHS England, and DHSC are piloting the secure linkage of police collision and healthcare data to better understand the causes and impacts of road traffic incidents. Using the Pre-hospital Research and Audit Network (PRANA) framework, this initiative will enhance analysis of injury severity, collision outcomes, and NHS burden. This work started in 2025 and the department has published an initial feasibility study which can be found on the government website with further updates expected over the next year.
Asked by: Gregory Campbell (Democratic Unionist Party - East Londonderry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 January 2026 to Question 106495, what assessment has been made of the reasons for the 25% reduction in the numbers of those aged 75 and over self referring for bowel cancer screening between 2023 and 2024.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Gareth Bacon (Conservative - Orpington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is planning to take to ensure that the final Equality Impact Assessment for the prostate cancer screening recommendation does not (a) continue and (b) worsen existing health inequalities for black men.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Calvin Bailey (Labour - Leyton and Wanstead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether any additional evidence published since the UK National Screening Committee’s draft recommendation in November will be considered before a final decision is made on prostate cancer screening.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Mary Glindon (Labour - Newcastle upon Tyne East and Wallsend)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of the abolition of NHS England on the commissioning, oversight and consistency of access to weight management services across England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.